Slide 1: Decoding Biology To Radically Improve Lives: End of Q2 2021
Decoding Biology To Radically Improve Lives End of Q2 2021 Exhibit 99.1
Slide 2: Forward-Looking Statements
This presentation and any accompanying discussion or documents may contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations, estimates and
Slide 3: Technology is disrupting the way we communicate, eat, move, work
Technology is disrupting the way we communicate, eat, move, work, exercise, travel, and so much more … Trademarks are the property of their respective owners and used for informational purposes only.
Slide 4: In biopharma, a decades long trend of increasing costs
… but in biopharma, a decades long trend of increasing costs Source: based on EvaluatePharma. Analysis is not inflation-adjusted. Analysis is not restricted to novel molecules, though it does exclude generics. Cumulative, 10-year trailing industry R&D spend per launch ($bn) Annual launches Cunulativ
Slide 5: Why have we not seen the same scale of improvements in drug discovery?
Why have we not seen the same scale of improvements in drug discovery and development efficiency?
Slide 6: Because biology is massively complex
In practicing, I may need a bit more time on this one, so maybe can we slow the animation down? Maybe double the time to zoom out? Because biology is massively complex
Slide 7: AI Expert Systems given way to Modern AI Automation
AI Expert Systems given way to Modern AI Automation Automation tools enable massive scale Storage 1M-Fold Decrease In Costs over 40 years Compute 1M-Fold Increase in Compute over 40 years Bio Tools Tools like CRISPR allow CONTROL of Biology Exponential improvements in technology are converging to en
Slide 8: 82M+ proprietary experiments, 9PB dataset, 179B+ inferred relationships
82M+ Proprietary experiments in human cells conducted in our own laboratories 9PB At 9 petabytes, one of the largest proprietary biological and chemical datasets 179B+ Inferred relationships between human genes, chemical compounds and more using our Map of biology 37 Human cell types onboarded to ou
Slide 9: The Recursion Operating System for industrializing drug discovery
The Recursion Operating System for industrializing drug discovery An integrated, multi-faceted system for generating, analyzing, and deriving insight from massive biological and chemical datasets to industrialize drug discovery. It is composed of: Infrastructure Layer Recursion Data Universe Recursi
Slide 10: Our OS enables scalable, unbiased exploration of biology
Our OS enables highly scalable, unbiased exploration of biology across multi-omics technologies, with phenomics (images) as a foundation… Recursion in-house software to design, manage and execute experiments Execute up to 1.7 million experiments each week in highly automated laboratories Generate hi
Slide 11: New investments in computational infrastructure and digital chemistry
…and new investments in computational infrastructure and digital chemistry demonstrate we are scaling our technology stack We have more data flux to the cloud than the firehose 9 PB of data served to scientists using Recursion software to generate insights In-house digital chemistry tools to in sili
Slide 12: A virtuous cycle of wet-lab and dry-lab side by side
Our OS learns and grows thanks to a virtuous cycle of wet-lab and dry-lab side by side
Slide 13: Meaningful leading indicators of industrializing drug discovery
Data shown is the average of all our programs since late 2017. All industry data adapted from Paul, et al. Nature Reviews Drug Discovery. (2010) 9, 203–214 We are demonstrating meaningful leading indicators of industrializing drug discovery and development Failing faster and earlier to … … spend les
Slide 14: Scale and breadth of active research and development programs
The power of the Recursion OS is demonstrated by the scale and breadth of active research and development programs
Slide 15: Choose Your Own Adventure: drug discovery as a search problem
Choose Your Own Adventure: We are transforming drug discovery into a search problem Immunology Using 82M+ proprietary experiments, we can algorithmically infer 179B+ biological relationships across the human genome, 100s of thousands of compounds and soluble factors to explore many therapeutic areas
Slide 16: Oncology: Known oncology pathways cluster together
Oncology: Known oncology pathways cluster together as expected Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Oncology Multiple oncology pathways cluster independently demonstrating ability to ident
Slide 17: Oncology: Novel targets can be identified
Oncology: Novel targets can be identified as they cluster with known biology Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Oncology Knockout of novel gene is inferred to be similar to PI3K gene fam
Slide 18: Neuroscience: Neuro-relevant pathways cluster together
Neuroscience: Neuro-relevant pathways cluster together as expected Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Neuroscience Gene knockout of mitochondrial and autophagy genes, highly relevant in
Slide 19: Neuroscience: Novel chemical insight
Neuroscience: Novel chemical insight provides fodder for discovery programs Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Neuroscience Similar Opposite Compounds with three distinct Mechanisms of A
Slide 20: Immunology: IL6/JAK biology recapitulates
Immunology: IL6/JAK biology recapitulates across gene knockouts and chemical substrate Immunology Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Knockout of IL6 gene family and dosing of cells with
Slide 21: Immunology: Novel chemical insight
Immunology: Novel chemical insight provides fodder for discovery programs Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Immunology A novel chemical series similar to IL6 gene knockout and opposite
Slide 22: Capital efficient business strategy with broad ambition
We leverage a capital efficient business strategy with broad ambition for the future Internal Pipeline - Rare Genetic Diseases Asset Sales / Licenses / Commercialization Partnership strategy Enterprise scale contracts Add knowledge to growing map of biology Internal Pipeline -- Capital Efficient Dis
Slide 23: A biotechnology company scaling more like a technology company
A biotechnology company scaling more like a technology company Forward program growth Significant program growth Growing economic opportunity Reduction of binary risks (1) ‘Unique Perturbations’ refers to the number of gene, soluble factor, cell and/or compound combinations physically explored. (2)
Slide 24: Comparison to relevant platform companies
Comparison to relevant platform companies Company Early Discovery – Preclinical Clinical / commercial assets 8 15 15 13 11 3 8 10 6 (multiple through collaboration) 1 2 44 4 Pipeline data from company websites as of 8/26/2021. Trademarks are the property of their respective owners and used for infor
Slide 25: Recursion is leading technology-enabled drug discovery
Recursion is leading technology-enabled drug discovery Trademarks are the property of their respective owners and used for informational purposes only.
Slide 26: Team Experience
Team Experience Full-time Employee Split Biology, Chemistry & Development ~40% Data Science, Software Engineering & Automation ~35% BD, Product, Administration, Legal, IP, etc. ~25% Advanced degrees (Ph.D. or M.D.) Employees today Team Credentials ~25% 300+ Gender: % Women ~45% ~40% Below VP VP and
Slide 27: Our leadership team brings together experience & innovation
Our leadership team brings together experience & innovation to build the operating system for scaling biopharma discovery Board of Directors TINA LARSON President & COO MASON VICTORS Chief Product Officer RON ALFA, MD/PHD SVP of Research Executive Team CHRIS GIBSON, PHD Co-Founder & CEO DEAN LI, MD/
Slide 28: Impact
Impact
Slide 29: Key Updates During Q2 2021
Key Updates During Q2 2021 Infrastructure Phenomics experiments executed during Q2 increased more than 30% QoQ Operating BioHive-1 Supercomputer Data Universe Proprietary biological data increased by >1 PB, total biological data now 9 PB >2x orthogonal transcriptomics and proteomics datasets Map/Inf
Slide 30: Induction Labs is a growth engine for additional market opportunities
Induction Labs is a growth engine for exploring additional market opportunities Recursion OS - Industrialize small molecule drug discovery broadly across biology Other Modalities including large molecules, and RNA therapeutics Diagnostics Finance Animal Health/ Smart Agriculture
Slide 31: REC-4881: MEK inhibitor for Familial Adenomatous Polyposis
REC-4881: Orally bioavailable MEK inhibitor for the potential treatment of Familial Adenomatous Polyposis (FAP) Disease Overview: Autosomal dominantly inherited rare tumor syndrome caused by mutations in APC gene affecting ~50,000 patients in US and EU5 Expected Milestone: First patient enrolled in
Slide 32: Planned Phase 2 trial design in classical FAP
Eligibility: ≥ 18 years of age with clinical diagnosis of FAP with more than 100 polyps prior to colectomy or APC gene mutation REC-4881 Dose A REC-4881 Dose B Placebo R 2:2:1 Responder REC-4881 or 24 Week Follow-up Non-Responder REC-4881 or Standard of Care Placebo REC-4881 or Standard of Care 45 d
Slide 33: REC-994: Potential treatment for Cerebral Cavernous Malformation
REC-994: First-in-disease, orally bioavailable potential treatment for Cerebral Cavernous Malformation (CCM) REC-994 reduces lesion number in chronic mouse models of CCM Disease Overview: Autosomal dominantly inherited neurovascular disease caused by mutations in CCM1, CCM2, or CCM3 genes affecting
Slide 34: Planned Phase 2 trial in Symptomatic CCM
≤ 8 weeks 52 weeks 4 weeks REC-994 Low Dose Placebo Eligibility: ≥ 18 years of age with anatomic CCM lesions demonstrated by MRI Follow-up Period REC-994 High Dose R 1:1:1 Planned Phase 2 Clinical Trial: Efficacy and Safety in Symptomatic CCM Patients REC-994: Planned Phase 2 trial to evaluate effic
Slide 35: REC-2282: HDAC inhibitor for Neurofibromatosis Type 2
REC-2282: First-in-class CNS-penetrant, orally bioavailable HDAC inhibitor for the potential treatment of Neurofibromatosis Type 2 (NF2) REC-2282 prevents growth of human vestibular schwannoma and meningioma tumor grafts in mouse studies Disease Overview: Autosomal dominantly inherited rare tumor sy
Slide 36: Planned adaptive Phase 2/3 trial in meningioma
Phase 2 Phase 3 REC-2282 Placebo Eligibility: ≥ 12 years of age with progressive NF2-mutated meningiomas R 2:1 Adaptive Phase 2/3 Trial to Evaluate the Efficacy and Safety in Meningioma Patients R 1:1 REC-2282 40 mg REC-2282 60 mg Interim Analysis Progression REC-2282: Planned adaptive Phase 2/3 tri
Slide 37: REC-3599: Potential treatment for GM2 gangliosidosis
REC-3599: First-in-class orally bioavailable, selective inhibitor of PKC and GSK3ß for the potential treatment of GM2 gangliosidosis (GM2) REC-3599 reduces autofluorescence substrate accumulation and GM2 aggregates in GM2 patient-derived fibroblasts Disease Overview: Pediatric lysosomal storage dise
Slide 38: Planned Phase 2 trial in infantile GM2 gangliosidosis
4 weeks 52 weeks 4 weeks Eligibility: Infants with documented diagnosis of infantile GM2 gangliosidosis Follow-up Period REC-3599 8 weeks REC-3599 Dose Escalation Planned Phase 2 Clinical Trial to Evaluate the Efficacy and Safety in Infantile GM2 Gangliosidosis REC-3599: Planned Phase 2 clinical tri
Slide 39: Additional notable programs moving through our pipeline
Additional notable programs moving through our pipeline C. difficile Colitis (REC-3964) Current status: preclinical New chemical entity with potential to be orally active, gut-biased, C. difficile toxin inhibitors via glycosyl transferase inhibition. C. difficile affects up to 730k patients annually
Slide 40: REC-3964: Toxin inhibitor for C. difficile infection
REC-3964: Orally active small molecule toxin inhibitor for prophylaxis and recurrent C. difficile infection C. difficile-infected model hamsters treated with REC-163964 survive longer than vehicle-treated animals Disease Overview: Infectious disease caused by Clostridium difficile affecting more tha
Slide 41: STK11: Small molecule to enhance anti-PD-(L)1 response
STK11: Orally bioavailable, small molecule to enhance anti-PD-(L)1 response of STK11 mutant cancers Disease Overview: STK11 is a tumor suppressor mutated in a variety of cancers Mutations in STK11 have been shown to underlie resistance of cancers to immune checkpoint inhibitors, especially in non-sm
Slide 42: Neuroinflammation: modulators of microglial activation
Neuroinflammation: Orally bioavailable, CNS-penetrant, small molecule modulators of microglial activation Disease Overview: Neuroinflammation is a hallmark of diseases of the CNS, including neurodegenerative diseases with hallmark of microglial activation and secretion of proinflammatory cytokines s
Slide 43: Cancer Immunotherapy Target Alpha
Cancer Immunotherapy Target Alpha: Inferential search identified targets and molecules active on checkpoint resistance pathways Pheno-similar Pheno-opposite BIRC2 Target Gene A BIRC2 Target Gene A CT26: mouse colon carcinoma. REC-A was dosed PO, QD for 5 weeks. Anti-PD-1 was dosed IP, BIW for 5 week
Slide 44: MYC: Small molecule inhibitors of MYC
MYC: Small molecule inhibitors of MYC for the treatment of MYC-driven cancers Disease Overview: MYC regulates diverse cellular processes involved in oncogenesis Gain-of-function alterations and amplifications in MYC have been identified in more than 50% of human cancers MYC pathway activation is obs
Slide 45: CMT2A: Therapeutic for Charcot-Marie Tooth Disease, Type 2A
CMT2A: Potential first-in-disease, orally bioavailable disease modifying therapeutic for Charcot-Marie Tooth Disease, Type 2A Disease Overview: Rare, autosomal dominant, peripheral nerve disease caused by mutations in MFN2 estimated to affect approximately 15,000 patients in US & EU5 and leads to pr